

Na prezentované kazuistice vidíme zajímavou kompletní radiologickou regresi plicního nálezu po léčbě sunitibem v první linii, další zajímavostí jsou výrazné regresivní změny v primárním nádoru ledviny po cílené léčbě. Parciální remise onemocnění trvala sedm měsíců.

## ZÁVĚR

I přes moderní cílenou léčbu, která vede u řady pacientů k remisi onemocnění, je mRCC závažné nevléčitelné onemocnění. Cílená léčba pacientů výrazně prodlouží život se zachováním jeho kvality.

## LITERATURA:

1. Dabestani S, Thorstenson A, Lindblad P, et al. Renal cell carcinoma recurrences and metastases in primary non-metastatic patients: a population-based study. *World J Urol* 2016; 34(8): 1081–1086.
2. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. *J Clin Oncol* 2002; 20(1): 289–296.
3. Fyfe G, Fisher RI, Rosenberg SA, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. *J Clin Oncol* 1995; 13(3): 688–696.
4. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. *N Engl J Med* 2007; 356(2): 125–134.
5. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. *Jama* 2006; 295(21): 2516–2524.
6. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. *J Clin Oncol* 2009; 27(22): 3584–3590.
7. Albiges L, Powles T, Staehler M, et al. Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma. *Eur Urol* 2019; 76(2): 151–156.
8. Gong J, Maia MC, Dizman N, Govindarajan A, Pal SK. Metastasis in renal cell carcinoma: Biology and implications for therapy. *Asian Journal of Urology* 2016; 3(4): 286–292.
9. Zhou L, Liu XD, Sun M, et al. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. *Oncogene* 2016; 35(21): 2687–2697.
10. Callea M, Albiges L, Gupta M, et al. Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma. *Cancer Immunol Res* 2015; 3(10): 1158–1164.
11. Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. *J Clin Oncol* 2006; 24(1): 25–35.
12. Najjar YG, Mittal K, Elson P, et al. A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma. *Eur J Cancer* 2014; 50(6): 1084–1089.
13. Staehler M, Haseke N, Zilinberg E, et al. Complete remission achieved with angiogenic therapy in metastatic renal cell carcinoma including surgical intervention. *Urol Oncol* 2010; 28(2): 139–144.
14. Mejean A, Ravaud A, Thezenas S, et al. Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma. *N Engl J Med* 2018; 379(5): 417–427.
15. Bex A, Mulders P, Jewett M, et al. Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial. *JAMA Oncol* 2019; 5(2): 164–170.
16. Dabestani S, Marconi L, Hofmann F, et al. Local treatments for metastases of renal cell carcinoma: a systematic review. *Lancet Oncol* 2014; 15(12): e549–561.